Objective: Resistin is a hormone that has been associated with metabolic syndrome and cardiovascular disease. The role of resistin in patients with peripheral artery disease (PAD) has not been fully explored. This study seeks to understand the relationship between serum resistin, vascular function, and cardiovascular outcomes in patients with PAD.
Resistin is an adipokine, a class of hormones released by adipocytes, that has been positively associated with fat mass 1 and insulin resistance. 2, 3 Although the physiologic role of resistin in humans remains unclear, it has been hypothesized to contribute to the well-established link between obesity and diabetes mellitus 4 as well as to the development of atherosclerosis. 5 Recent evidence has demonstrated that elevated resistin levels are associated with incidence and severity of coronary artery disease (CAD), 6 heart failure, 7 and adverse cardiovascular events. 7 The mechanisms through which resistin could cause atherogenesis and result in poor cardiovascular outcomes have been examined in animal models and in patients without peripheral artery disease (PAD). 5 Resistin has been reported to be associated with impaired vascular function, 5, 8 which is associated with the development of atherosclerosis, 9 perioperative events, 10 and poor cardiovascular outcomes. 11 Whereas resistin and its effects on vascular disease are complex, its link to adverse cardiovascular events has been reported in patients with and without a history of cardiovascular disease. [12] [13] [14] Although the role of resistin has been explored in patients with cardiovascular disease, literature specific to patients with PAD is sparse. There is limited evidence suggesting that levels of serum resistin are elevated in patients with PAD. [15] [16] [17] In addition, resistin has been associated with PAD severity and reduced amputation freesurvival, suggesting that this hormone may play an important role in patients with PAD. 18 Exploration of resistin as a surrogate marker or effector of impaired vascular function and poor outcomes may identify resistin as a valuable prognostic marker or therapeutic target among patients with PAD. The objective of this study was to assess the relationship between serum resistin and vascular physiology measures (endothelial function and arterial stiffness) and the rate of major adverse cardiac events (MACEs) in patients with PAD. It was hypothesized that elevated serum resistin is associated with increased vascular stiffness, decreased endothelial function, and increased rate of MACEs.
METHODS

Study participants
There were 106 patients presenting with PAD who were recruited between April 2011 and July 2016 from the vascular surgery outpatient clinic at the San Francisco Veterans Affairs Medical Center (SFVAMC). Participants were defined as having PAD if they had symptoms of claudication and an ankle-brachial index (ABI) <0.9 or if they had a prior history of peripheral revascularization for symptomatic PAD, regardless of ABI. Additional inclusion criteria included age of at least 35 years and patients who had no severe hepatic (Child-Pugh class $B), renal (creatinine concentration $2 mg/dL), or nonvascular inflammatory disease. Patients were excluded if they had a severe acute illness within the last 30 days or were taking any immunosuppressive medications. Several patients included in this study had originally participated in the Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation (OMEGA-PAD I) trial (NCT01310270), which measured the effects of 1 month of fish oil supplementation on inflammation, endothelial function, and arterial stiffness. 19 Because this trial assessed inflammatory profiles, several of the inclusion criteria listed before were used. In addition, this trial studied patients with "stable claudication," which was defined as Rutherford categories 1 to 3 or a history of revascularization for claudication; therefore, patients with critical limb ischemia were excluded. Institutional Review Board approval was granted for this study by the Committee on Human Research at the University of California, San Francisco, as well as by the SFVAMC Research and Development Office, with all participants giving informed written consent.
Measurements
Demographics, medical comorbidities, and anthropometrics. Demographic variables including age, sex, and race were collected for all study participants through an intake questionnaire. Medical comorbidities including hyperlipidemia, hypertension, diabetes, and CAD were collected using the SFVAMC electronic medical record. Patients provided information about their current use of insulin, oral diabetes medications, aspirin, beta blockers, statins, or angiotensin-converting enzyme (ACE) inhibitors. ABI was measured in each lower extremity using previously established techniques. 20 Flow-mediated vasodilation (FMD). Endothelial function was measured by brachial artery FMD using previously described methods. 21 Radial artery tonometry. Arterial stiffness was measured in a subset of patients (n ¼ 60) with an applanation tonometer using the SphygmoCor system (AtCor Medical, Sydney, Australia). Calculation of the augmentation index (AIX) as well as more detailed descriptions for tonometry measurements have been previously published. 21, 22 Briefly, radial artery tonometry was measured by applying the SphygmoCor applanation tonometer to the right wrist. The AIX was then able to be calculated using pulse wave analysis because of the observation that the arterial waveform being examined is a composite of an anterograde pulse wave plus a component of the preceding wave that was reflected backward off of the arterial wall. Stiffer arteries are characterized by higher augmented pressures because of the collision and combination of the anterograde and retrograde pulse waves. 23, 24 Calculation of the AIX, which is defined as [augmented pressure/(systolic blood pressure e diastolic blood pressure)], was then completed using the SphygmoCor's proprietary software. 24 The peripheral AIX was calculated directly, and the central AIX was approximated using previously validated transfer equations 25 that are routinely used. 26 The central AIX was then normalized to 75 beats/min to adjust for variations in heart rate. Laboratory tests. A blood sample was obtained from each participant while in a fasting state at the initial study visit for measuring lipids, hemoglobin A 1c , estimated glomerular filtration rate (eGFR), and high-sensitivity C-reactive protein (hsCRP). Resistin was measured using a commercially available enzyme-linked immunosorbent assay kit from R&D Systems (Minneapolis, Minn) according to the manufacturer's instructions by a core research laboratory. Each enzyme-linked immunosorbent assay was run twice for each participant and for samples with a constant of variance <20%, the average value retained.
MACEs. The patients' electronic medical records were retrospectively reviewed for the occurrence of MACEs, which were defined as myocardial infarction (MI), coronary revascularization, transient ischemic attack, stroke, or death from a cardiac cause, 27 with enrollment in the study as the time of origin and December 2016 as the end of the study period. MI was defined as a detected rise in cardiac markers >99th percentile with at least one of the following: ischemic symptoms, new ST elevation or left bundle branch block, development of Q waves, imaging evidence of loss of viable myocardium, or coronary thrombus identified by coronary angiography.
Statistical analysis
All statistical analyses were performed using Stata version 15.0 (StataCorp LLC, College Station, Tex). Patients were stratified into groups by resistin quartile to assess differences in baseline characteristics while still providing some granularity in regard to the association of levels of resistin with endothelial function. Quartiles of resistin were based on the median level of resistin in the cohort. Summary statistics were reported using mean and standard deviation for continuous variables along with frequency and percentage for categorical variables. Differences between resistin quartile groups were calculated using analysis of variance with Bonferroni-corrected post hoc pairwise comparisons for normally distributed continuous variables, KruskalWallis test for continuous variables without a normal distribution (pack-years smoked, hsCRP, and triglycerides), and Fisher exact test for categorical variables.
Unadjusted univariate linear regressions were performed to measure the relationship between resistin quartiles and FMD, peripheral AIX, and central AIX, normalized to 75 beats/min. Multivariable models were built to adjust for other demographics and comorbidities of the patients. Bivariate screening was used to select covariates for the multivariable models. In the bivariate analyses, resistin quartiles were used as the primary predictor of FMD, and several demographic characteristics and comorbidities were examined individually as potential covariates. Any covariate associated at the level of P # .20 was included in the multivariable model. Body mass index (BMI) and diabetes mellitus were included in the model a priori because of their previously reported relationship with resistin. 1, 3 Cox proportional hazards models were used to calculate hazard ratios (HRs) for MACEs, using enrollment in the study as the time of origin. Because of the small number of events, resistin was modeled as a continuous variable in the Cox models rather than in quartiles. An initial model was built using resistin as the primary predictor of MACEs. To determine whether the relationship between resistin and MACEs was influenced by inflammatory status, a subsequent model was performed that also adjusted for hsCRP. A final multivariable model was then built in a stepwise fashion using a P value cutoff of P < .10.
RESULTS
Study participants had a mean age of 68 6 8 years; they were largely white (75%) and male (97%) and had comorbidities commonly associated with PAD, including hypertension (92%), hyperlipidemia (87%), CAD (37%), and diabetes mellitus (38%). Patients were then stratified into groups by resistin quartile (I, 2.6-5.9 ng/mL; II, 6.0-7.8 ng/mL; III, 7.9-10.5 ng/mL; IV, 10.6-24.3 ng/mL). Baseline demographics and characteristics of the patients are reported by resistin quartile in Table I . The mean age increased and eGFR decreased significantly with increasing resistin quartile. There was no significant difference in comorbidities, medication use, or PAD severity, as measured by Rutherford categories or ABI, between groups. FMD decreased significantly by increasing resistin quartile (Table II) . A Bonferroni post hoc analysis identified significant differences between resistin quartiles I and III (P ¼ .006) and I and IV (P ¼ .004; Fig 1) (Table III) . Relative to the lowest resistin quartile (I), quartiles III and IV were independently associated with an absolute difference in FMD of À2.26% and À2.53%, respectively. There was no significant difference in the peripheral AIX or central AIX, normalized to 75 beats/min, between resistin quartiles (Table II) .
During a median follow-up period of 36 months (interquartile range, 29-45 months), 21 patients experienced a MACE (event rate of 20%). These events included 13 MIs or coronary revascularizations, 5 deaths from a cardiac cause, 2 strokes, and 1 transient ischemic attack. Patients in the fourth quartile of resistin had a higher risk of MACEs than patients in the first quartile (Fig 2) . A univariate Cox proportional hazards model identified that resistin was associated with an increased rate of MACEs (HR, 1.09; 95% CI, 1.01-1.18; P ¼ .03), and adjustment for hsCRP did not affect the results. The final multivariable Cox proportional hazards model included CAD, tobacco use status, and age, which was added a priori. Other covariates included in the development of the model were white ethnicity, BMI, FMD, pack-years smoked, diabetes mellitus, hyperlipidemia, hypertension, hsCRP, eGFR, and medication use (insulin, oral diabetes medications, aspirin, beta blocker, statin, or ACE inhibitor). The resulting multivariable model revealed that serum resistin was independently associated with an increased rate of MACEs (HR, 1.10; 95% CI, 1.003-1.200; P ¼ .04; Table IV) . These results indicate a 10% higher rate of MACE for every 1 ng/mL increase in serum resistin. This would suggest a nearly 220% higher rate of MACEs in comparing the lowest level of resistin with the highest level of resistin in this cohort. A sensitivity analysis including FMD as a covariate in this model did not significantly alter the association, suggesting that resistin is associated with an increased rate of MACEs, independent of its association with endothelial function. An additional sensitivity analysis that adjusted for only CAD and patients' characteristics that were significantly different between baseline resistin quartile groups (age, pack-years, eGFR, and FMD) yielded results similar to the initial model (HR, 1.13; 95% CI, 1.01-1.25; P ¼ .03).
DISCUSSION
This study is the largest assessment of the relationship between serum resistin, vascular function, and incident MACEs in patients with PAD. These results demonstrate that in a cohort of patients with PAD, elevated serum resistin is independently associated with impaired endothelial function, as measured by brachial artery FMD, and an increased rate of MACEs. There was no observed association between resistin and arterial stiffness, as measured by the peripheral AIX and central AIX, normalized to 75 beats/min. These findings suggest that resistin may be a novel biomarker or effector of impaired endothelial function in patients with PAD. Moreover, resistin may be a novel predictor of MACEs in a population with a high prevalence of traditional cardiovascular risk factors.
Results of this study suggest that among patients with PAD, serum resistin is not positively associated with fat mass, as BMI was not significantly different between resistin quartiles. In addition, there were no differences observed in medication use between resistin quartiles, which suggests that these medications may have limited or no effect on serum resistin levels in patients with PAD. Consistent with results of this study, previous reports suggest that beta-blocker, ACE inhibitor, and statin use is not associated with lower levels of serum resistin. 28, 29 However, there are currently only a limited number of studies that measure the impact of medication use on serum resistin levels. Prospective studies or randomized clinical trials of patients with PAD would be required to more accurately assess the effect of medication use on resistin levels in this population of patients.
Studies with small sample sizes have demonstrated that elevated resistin is associated with impaired FMD in healthy individuals 30 and in patients with metabolic syndrome but without cardiovascular disease. 31 To date, only one study has examined this association in patients with PAD. In a cohort of 60 patients with intermittent claudication, Golledge et al 32 reported that serum resistin was not correlated with FMD (r ¼ À0.11; P ¼ .42); however, this study may have been underpowered to detect a significant correlation. Several mechanisms linking resistin and endothelial function have been described in the basic science literature. Resistin has been reported to increase cellular levels of reactive oxygen species that can impair endothelium-dependent vasodilation by decreasing nitric oxide synthesis in porcine 33 and human coronary artery endothelial cells. 34 Resistin has also been reported to increase vasoconstriction of endothelial cells by promoting the release of the local vasoconstrictor endothelin 1. 35 Resistin could further contribute to endothelial dysfunction by upregulating the expression of the adhesion molecules vascular cell adhesion molecule 1 36 and intracellular adhesion molecule 1 36 as well as the chemokine monocyte chemotactic protein 1. 35 The role of resistin in endothelial cell dysfunction has further been implicated with a downregulation of tumor necrosis Never smoker 2 (7) 1 (4) 1 (4) 4 (15) Former smoker 13 (48) 18 (69) 14 (52) 12 (46) Current smoker 12 (45) 7 (27) 12 (44) 10 (39) Pack No claudication 0 (0) 1 (4) 0 (0) 1 (4) Mild claudication 6 (22) 10 (38) 7 (26) 7 (27) Moderate claudication 12 (44) 6 (23) 9 (33) 4 (15) Severe claudication 9 (33) 9 (35) 11 (41) Categorical variables are presented as number (%). Continuous variables are presented as mean 6 standard deviation. Boldface P values were below the .05 level required for statistical significance. a Quartile I, 2.6 to 5.9 ng/mL; quartile II, 6.0 to 7.8 ng/mL; quartile III, 7.9 to 10.5 ng/mL; quartile IV, 10.6 to 24.3 ng/mL.
b Calculated using a c 2 test for categorical variables, analysis of variance for normally distributed continuous variables, and a Kruskal-Wallis test for continuous variables without a normal distribution (pack-years, hsCRP, and triglycerides).
factor receptor-associated factor 3, 35 which is a potent inhibitor of CD40 ligand-mediated endothelial cell activation. In addition to having several actions that directly affect endothelial cells, resistin has been associated with increased local 37 and systemic inflammation, 38 which may further contribute to impaired endothelial function. However, previous reports suggest that inflammation contributes to only a portion of resistin's effects. 39 This is consistent with the results of the multivariable model reported in this study, which found that adjustment for hsCRP did not affect the results. In addition, renal dysfunction, as measured by eGFR, was statistically significantly lower with increasing resistin quartiles and independently associated with impaired FMD. Both of these findings are consistent with previous reports 40, 41 and suggest that the findings in this study have external validity.
In the context of these proposed mechanisms, the findings of this study suggest that resistin may be implicated in the pathogenesis of PAD in part by its effects on endothelial dysfunction. However, without a control group, further interpretation of the potential role that resistin may play in the pathogenesis of PAD is limited. Further research is required to determine whether resistin is a true causal determinant of impaired endothelial function in patients with PAD, which has the potential to provide an opportunity for targeted interventions to prevent the progression of disease. Alternatively, resistin may represent a novel biomarker of impaired FMD in this population of patients, which would offer a net advantage over the more time-consuming and complex measurement of FMD.
The relationship between serum resistin and MACEs in patients with CAD is well supported 42 and consistent with the findings in this cohort of patients with PAD. In a prospective nested case-control study of postmenopausal women, increased resistin was associated with an increased risk of incident stroke, independent of traditional stroke risk factors, endothelial function, and markers of inflammation. 12 The prospective Health, Aging, and Body
Composition Study reported that increased resistin was independently associated with an increased risk of nonfatal MI and cardiac event-related mortality among patients aged 70 to 79 years. 13 Similarly, in a study of 140 patients undergoing percutaneous coronary intervention, elevated resistin was associated with an increased risk of MACEs at 3-month follow-up.
14 Calculated using an analysis of variance. Although the effect size of the reported relationship between resistin and MACEs was modest, this association was independent of age and CAD, both of which are strongly associated with MACEs. In addition, the high prevalence of traditional cardiovascular risk factors typically present in patients with PAD makes existing risk prediction tools less useful in predicting adverse cardiovascular events. As such, identification of novel predictors of cardiovascular risk in patients with PAD is important to be able to identify high-risk patients. Future studies should consider examining the incremental predictive benefit of including serum resistin in traditional models of risk prediction. Mechanisms have been proposed to mediate the relationship between resistin and rate of MACEs. These hypothesized mechanisms include resistin's ability to increase vascular smooth muscle cell migration, 43 plaque instability by the increased expression of CD40 ligand, 35, 44 adhesion molecule expression, 36 and systemic inflammation. 45 However, several studies, including this study, have identified a significant relationship between resistin and adverse cardiac events even after adjusting for hsCRP. 42 Menzaghi et al 46 recently reported the correlation of resistin with several cytokines that were found to be associated with an increased rate of MACEs. Although adjusting for hsCRP did not significantly alter the relationship between resistin and MACEs in this cohort, it is possible that hsCRP alone is not representative of the full effects that resistin may have on inflammatory pathways and is not an adequate measurement of systemic inflammation. Given the previous evidence presented, it is likely that resistin affects several pathways that increase the risk of MACEs. Reports on the relationship between resistin and arterial stiffness are heterogeneous. Serum resistin has been significantly positively associated with arterial stiffness in healthy individuals 47 and patients with CAD 48 but not in patients with resistant hypertension 49 or patients on hemodialysis. 50 Similar to the association of resistin and endothelial function, studies that have assessed the relationship between resistin and arterial stiffness in patients specifically with PAD are lacking. The results of this study suggest that resistin may not be associated with increased arterial stiffness but is associated with impaired endothelial function in patients with PAD. As our understanding of the mechanisms underlying PAD improve, it will be important to consider how resistin inter-relates with each of these functions. Identifying the roles that resistin may play may allow a more thorough understanding of all of the factors that mediate PAD.
Limitations. The small sample size and small number of MACEs reduce power. Arterial stiffness was measured in only a subset of the cohort (n ¼ 60), which further reduced power in those analyses and might have limited the ability to identify a statistically significant relationship. It was not able to be determined whether changes in FMD were influenced by alterations in smooth muscle cells as nitric oxide-independent vasodilation was not examined in all participants. The population of patients is representative of the veterans population (mostly male and white) and might not be generalizable to the rest of the U.S. population. Furthermore, because this study did not include a control group of patients without PAD, differences in serum resistin between patients with and without PAD were not measured.
CONCLUSIONS
Resistin was independently associated with impaired endothelial function but not with arterial stiffness in patients with PAD. In addition, resistin predicted an increased rate of adverse cardiac events independent of inflammatory status and endothelial function. Results of this study support the continued exploration of resistin as a predictor of adverse cardiac events and poor operative outcomes in patients with PAD. Further research is needed to determine the potential mechanisms by which resistin may increase MACEs or impair endothelial function and to explore the potential role of resistin in the pathogenesis of PAD. Prospective studies are needed to determine whether decreasing resistin has therapeutic benefit in patients with PAD. Kaplan-Meier analysis showing that increased serum resistin is associated with an increased rate of major adverse cardiac events (MACEs) in patients with peripheral artery disease (PAD; log-rank, P ¼ .02). 
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